ONWARD Medical raises EUR 50.85M for spinal cord injury neurostimulation therapies
Summary
ONWARD Medical has raised EUR 50.85 million through a private placement of new ordinary shares to advance its ARC Therapy platform for spinal cord injury. The funding was anchored by Ottobock, Invus, and ASR Global Impact Equity Fund. Proceeds will fund development of the investigational ARC-IM System, expand commercialization of the FDA-cleared ARC-EX System, and scale operations across the US and Europe.
Why it matters
ONWARD Medical's funding extends its cash runway through at least the end of 2026 and supports its mission to restore movement, function, and independence in people with spinal cord injuries. The company has received ten FDA Breakthrough Device designations and is pioneering the first BCI-enabled system to restore thought-driven movement after paralysis, positioning it as a leader in neurostimulation therapeutics.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial